Logo do repositório
 
Publicação

Managing schizophrenia with affective, sexual, metabolic and substance-use comorbidities: pharmacological considerations from an expert consensus

2026-12-01Artigo de investigação Acesso aberto
Ver registo simples
dc.contributor.authorVieta, Eduard
dc.contributor.authorMontejo, Ángel L.
dc.contributor.authorPillinger, Toby
dc.contributor.authorDell’Osso, Bernardo M.
dc.contributor.authorDimitraka, Maria
dc.contributor.authorFarooq, Saeed
dc.contributor.authorJesus, Gustavo
dc.contributor.authorTorres, Carlos Parro
dc.contributor.authorWobrock, Thomas
dc.contributor.authorPappa, Sofia
dc.date.accessioned2026-02-16T14:50:27Z
dc.date.available2026-02-16T14:50:27Z
dc.date.issued2026-12-01
dc.description.abstractBackground: Schizophrenia is a complex psychiatric disorder frequently complicated by comorbidities that contribute to functional impairment, poor treatment adherence, and elevated mortality. Among the most prevalent and burdensome are affective symptoms, sexual dysfunction, metabolic disturbances, and substance use disorders, which remain underrecognized and insufficiently addressed in routine care. Objectives: This expert consensus aimed to develop comorbidity-informed pharmacological strategies for schizophrenia, grounded in real-world challenges and individualized treatment needs. Methods: A multidisciplinary panel of 10 European psychiatrists convened for an in-person meeting. Four expert-led presentations, each addressing a key comorbidity, were followed by open discussion. A modified two-round Delphi process was subsequently used to validate the consensus statements, which were thematically synthesized into actionable recommendations. Results: Consensus-based recommendations were developed across four comorbidity domains, integrating current evidence with real-world clinical expertise. The panel emphasized the importance of individualized, patient-centered pharmacological strategies that balance efficacy, tolerability, and long-term functional outcomes. Partial dopamine agonists and other metabolically or hormonally favorable agents were identified as clinically useful across several comorbid profiles. Recommendations also addressed the optimization of antipsychotic selection, management of treatment-emergent side effects, and coordinated care for patients with dual diagnosis (also referred to as co-occurring disorders). Measurement-based monitoring and integrated service models were consistently highlighted as essential for improving outcomes. Conclusions: Effective management of schizophrenia requires a shift toward comorbidity-informed, recovery-oriented pharmacological care. These expert recommendations provide practical strategies to support individualized treatment planning in real-world clinical settings.eng
dc.identifier.citationVieta, E., Montejo, Á. L., Pillinger, T., & Dell’Osso, B. M. et al. (2026). Managing schizophrenia with affective, sexual, metabolic and substance-use comorbidities: pharmacological considerations from an expert consensus. Annals of General Psychiatry, 25(1), Article 3. https://doi.org/10.1186/s12991-025-00620-7
dc.identifier.doi10.1186/s12991-025-00620-7
dc.identifier.eid105028946300
dc.identifier.issn1744-859X
dc.identifier.other258e0838-340e-4dcc-9f90-095d7903329c
dc.identifier.pmcPMC12859896
dc.identifier.pmid41466278
dc.identifier.urihttp://hdl.handle.net/10400.14/57059
dc.identifier.wos001674836500001
dc.language.isoeng
dc.peerreviewedyes
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAffective symptoms
dc.subjectAntipsychotics
dc.subjectComorbidities
dc.subjectIndividualized treatment
dc.subjectMetabolic disturbances
dc.subjectPharmacological management
dc.subjectReal-world practice
dc.subjectSchizophrenia
dc.subjectSexual dysfunction
dc.subjectSubstance use disorders
dc.titleManaging schizophrenia with affective, sexual, metabolic and substance-use comorbidities: pharmacological considerations from an expert consensuseng
dc.typeresearch article
dspace.entity.typePublication
oaire.citation.issue1
oaire.citation.titleAnnals of General Psychiatry
oaire.citation.volume25
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
141042002.pdf
Tamanho:
2.19 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

FM - Contribuições em Revistas Científicas / Contribution to Journals